DNA X, Inc. Regains Nasdaq Compliance, Placed on One-Year Monitor

What Happened DNA X, Inc. (NASDAQ: SONM) announced in an 8-K that on August 28, 2026 it received a letter from the Nasdaq Hearings Panel notifying the company it has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires at least $2.5 million in stockholders’ equity. The Panel’s decision was dated July 24, 2026, and the company was informed that its securities remain subject to delisting if it fails to maintain compliance with all Nasdaq rules through November 18, 2026.

Key Details

• Nasdaq Listing Rule referenced: 5550(b)(1) — stockholders’ equity requirement of $2.5 million.
• Panel decision dated July 24, 2026; company received notification on August 28, 2026.
• Securities remain at risk of delisting for failures to comply through November 18, 2026.
• Nasdaq will impose a mandatory panel monitor under Rule 5815(d)(4)(B) until August 28, 2027; if the company falls out of compliance during that year, Nasdaq staff will issue a delisting determination without allowing a compliance plan or cure period, though the company may request a hearing.

Why It Matters Regaining compliance removes an immediate delisting deficiency tied to the $2.5M equity requirement, which is positive for maintaining the company’s Nasdaq listing. However, the mandatory one-year monitoring period and the rule that Nasdaq will not permit a compliance plan or cure if the company again falls out of compliance during that year increase the risk of a faster delisting process if problems recur. Investors should note the key dates (Nov 18, 2026 and Aug 28, 2027) and monitor the company’s future filings for any signs of renewed noncompliance or changes in equity/financial condition.